MetaVia Inc.

MetaVia Inc. is a clinical-stage biotechnology company focused on developing therapies for cardiometabolic diseases, including obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's lead asset, DA-1726, is a novel oxyntomodulin analogue that functions as a dual GLP-1 receptor and glucagon receptor agonist, currently in Phase 1 clinical trials for obesity. DA-1726 demonstrated 9.1% mean body weight loss at 48 mg after eight weeks without titration in Phase 1 studies, along with reductions in waist circumference, HbA1c, and liver stiffness. The company's second program, vanoglipel (DA-1241), is a potential first-in-class oral GPR119 agonist for MASH that has completed a Phase 2a study demonstrating direct liver benefits and glucose control. MetaVia is a pre-revenue company with no approved products. The company licensed its drug candidates from Dong-A ST Co. Ltd. and trades on the Nasdaq under the ticker MTVA. MetaVia has no debt and approximately $12.6 million in cash as of June 30, 2026, which it expects to fund operations through 2026. Updated Aug 6, 2026